Embed Size (px)
Citation preview
Opal Biosciences Limited is an innova2ve player in infec2ous disease treatment. An Australian biotechnology company commi<ed to tackling a serious
global health threat.
Corporate Presentation!May 2015
Julie Phillips, Managing Director
SAFE HARBOUR STATEMENT!
This presenta,on is provided to you for informa,on purposes only and should not be construed as investment advice or an offer, and shall not form part of an offer, or solicita,on to buy or sell any securi,es or deriva,ves. It should not be considered as an invita,on to subscribe for or purchase any securi,es in Opal Biosciences Limited (“Opal”), or as an inducement to make an offer or invita,on with respect to those securi,es. No agreement to subscribe for securi,es in Opal will be entered into on the basis of this presenta,on. This presenta,on contains forward-‐looking statements which are based on an assessment of present economic and opera,ng condi,ons, and on a number of assump,ons regarding future events and ac,ons that, at the date this presenta,on was prepared, are expected to take place. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertain,es, assump,ons and other important factors, many of which are beyond the control of Opal. Opal cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward looking statements contained in this presenta,on will actually occur and you should not place reliance on these forward looking statements. To the maximum extent permiIed by applicable laws, Opal and its affiliates make no representa,on and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authen,city, validity, accuracy, suitability or completeness of, or any errors in or omission, from any informa,on, statement or opinion contained in this presenta,on. The contents of this presenta,on are confiden,al. The presenta,on is being provided to you on the condi,on that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior wriIen permission of Opal.
IN THE HEADLINES!
“A post-‐an2bio2c era—in which common infec2ons and minor injuries can kill—far from being an apocalyp2c fantasy, is instead a very real possibility for the 21st century.” 2014 WHO Report “An,microbial Resistance: Global Report on Surveillance”
OBAMA’S PLAN TO FIGHT SUPERBUGS
President Barack Obama has commiIed US$1.2 billion in his annual budget to comba,ng drug resistant bacteria – double the current federal spend.
23,000 people die yearly from an,bio,c resistant bacterial infec,ons in the U.S. and more than 2 million fall ill, according to the Centers for Disease Control. (ref hIp://www.cdc.gov/drugresistance/threat-‐report-‐2013/)
WHAT HAPPENS IF WE FAIL TO ACT?
A report commissioned by Bri,sh Prime Minister David Cameron reveals the alarming reality we could face if we fail to fight
an,bio,c-‐resistant superbugs.
By 2050…
An average of 10 million people will die every year and it could cost the global economy up to $100 trillion.
J. O’Neill: An,microbial Resistance: Tackling a crisis for the health and wealth of na,ons, Dec 2014
GLOBAL HEALTH CHALLENGES
Rising anEbioEcs resistance, a threat to healthcare systems
worldwide
Hard-‐to-‐treat fungal infecEons problema,c for pa,ents with
weak immune systems
Few new drugs, the an,bio,cs pipeline is
running dry
Increase in prevalence, due to factors such as
climate change
MARKET SIZE!
Global anEfungals market,
US$13.9 billion
Global anEbacterials market, US$46 billion by 2019
Global anE-‐infecEves market, US$103 billion by 2015
Ref: Global An,fungal Therapeu,cs Market: Trends and Opportuni,es (2014-‐2019) Daedal Research, August 2014 An,-‐infec,ves – A Global Strategic Business Report, Global Industry Analysts, Inc. MCP-‐6156, February, 2010. An,bacterial Drugs Market-‐ A Global Industry Analysis, Size, Share, Growth, trends and Forecast, 2013-‐2019, Transparency Market Research, March 2014.
INTRODUCING OPAL TECHNOLOGY!
• Opal Technology has demonstrated ac,vity against a wide range of human disease causing germs.
• Poten,al to combat dangerous superbugs • Being assessed as a bioterrorism counter-‐measure • Poten,al applica,ons: injec,ons, eye drops, tablets, creams
BIOTERRORISM COUNTER-MEASURE!
Opal Technology – screened as a poten,al biological weapons counter-‐measure by the U.S. Army Medical Research Ins,tute of
Infec,ous Diseases (USAMRIID).
POTENTIAL PRODUCT LINE
Topical Use (Cream, ointment, spray) Intravenous Use (InjecEon)
Aimed at: Fungal infec,ons in the bloodstream, lungs and other body cavi,es e.g. sinuses. And bacterial infec,ons that cause blood poisoning, urinary tract infec,ons and pneumonia.
Aimed at: Skin, sof ,ssue and mucous membrane infec,ons, such as ,nea, conjunc,vi,s and external ear infec,ons, along with burns.
POTENTIAL PRODUCT LINE
Oral Use (Tablets, capsules, syrup, mouthwash)
Lung (InhalaEon)
Aimed at: Germs that cause gut infec,ons such as gastroenteri,s.
Aimed at: Chronic diseases such as cys,c fibrosis where lung infec,on is a major cause of illness and death.
OPAL’S DEVELOPMENT PLAN
With an interna,onal team and development plan in place, Opal Biosciences Limited is seeking an investment of AUD$3.5m to develop its Technology. • Opal-‐I, an injectable product • Opal-‐T, topical product
Our commercial objecEve is to out-‐license or sell the technologies to a larger pharmaceuEcal company for clinical trials and markeEng.
OPAL PRODUCTS PIPELINE
OPAL’S DEVELOPMENT TIMELINE !(Indicative)
INVESTMENT POTENTIAL!
• An,-‐infec,ves market large and growing
• Few compe,tors in development
• Government incen,ves in place
• Major pharmas returning to the sector and buying innova,on
• Opal Technology’s poten,al
• Experienced interna,onal team
BIG PHARMAS BUY UP INNOVATION
SMALL BIOTECHS PLAY BIG ROLE!
Small biotech companies are developing 80 percent of the an,bio,cs in the pipeline. “No single company can meet all the challenges alone, which is why we’re ac2vely par2cipa2ng in private-‐ and public-‐sector partnerships to address key barriers to effec2ve an2bio2c development.” — Alisha Mar,n, spokesperson, AstraZeneca
hIp://www.healthline.com/health/an,bio,cs/why-‐pipeline-‐running-‐dry
US GOVERNMENT INCENTIVES!
1. The GAIN (GeneraEng AnEbioEc IncenEves Now) LegislaEon 2. FDA’s Priority Review: FDA’s goal is to take ac,on on an
applica,on within 6mths (compared to 10mths).
3. Orphan Drug DesignaEon: Sponsor of the drug en,tled to development incen,ves (tax credits, extended market exclusivity).
4. FDA’s Fast Track Process: Designed to facilitate the development, and expedite the review of much needed new treatments.
GLOBAL COLLABORATIONS!
The Opal Technology project brings together a wealth of internaEonal experEse.
hIp://www.niaid.nih.gov/LabsAndResources/resources/dmid/invitro/Pages/invitro.aspx
hIp://www.niaid.nih.gov/labsandresources/resources/dmid/animalmodels/Pages/default.aspx
CAPITAL RAISING!
Opal Biosciences Limited is seeking an investment of AUD$3.5 million to develop its, Opal-‐I and Opal-‐T products.
Summary of the offer: Share issue price: AUD$0.20 Number of shares on issue: 10,000,000 (+ 5,000,000 op,ons) OpEons @ 26c: 1 for 2 for subscrip,ons received un,l 15 Jul 2015; then 1 for 4 for subscrip,ons received un,l 15 May 2016 OversubscripEons: of up to $500,000 may be accepted Fully diluted post-‐issue: 45,000,000 Opens: 15 May 2015 Closes: 15 May 2016
CONTACT US!
For further informaEon contact: Julie Phillips, Managing Director Tel: +61 (03) 9692 7240 Email: [email protected]
Opal Biosciences Limited is an innova2ve player in infec2ous disease treatment. An Australian biotechnology company commi<ed to tackling a serious
global health threat.
Corporate Presentation!May 2015
Julie Phillips, Managing Director
